Sandbox Impetigo ammu: Difference between revisions
Jump to navigation
Jump to search
(Created page with "===Impetigo=== * Impetigo, adult :* Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci) ::* '''Limited number...") |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
===Impetigo=== | ===Impetigo=== | ||
* Impetigo, adult | * Impetigo, adult<ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910 }} </ref><ref name="pmid24947530">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al.| title=Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. | journal=Clin Infect Dis | year= 2014 | volume= 59 | issue= 2 | pages= 147-59 | pmid=24947530 | doi=10.1093/cid/ciu296 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24947530 }} </ref> | ||
:* Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci) | :* Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci) | ||
::* '''Limited number of lesions''' | ::* '''Limited number of lesions''' | ||
| Line 34: | Line 34: | ||
::* '''Methicillin-resistant Staphylococcus aureus''' | ::* '''Methicillin-resistant Staphylococcus aureus''' | ||
:::* Preferred regimen: [[Clindamycin]] 25–30 mg/kg/day PO tid for 7 days {{or}} [[Sulfamethoxazole-Trimethoprim]] 8–12 mg/kg/day PO bid for 7 days | :::* Preferred regimen: [[Clindamycin]] 25–30 mg/kg/day PO tid for 7 days {{or}} [[Sulfamethoxazole-Trimethoprim]] 8–12 mg/kg/day PO bid for 7 days | ||
==References== | |||
{{reflist|2}} | |||
Latest revision as of 14:30, 13 August 2015
Impetigo
- Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci)
- Limited number of lesions
- Preferred regimen: Mupirocin topically bid for 5 days OR Retapamulin topically bid for 5 days
- Numerous lesions or outbreaks of post streptococcal glomerulonephritis
- Preferred regimen: Dicloxacillin 250 mg PO qid for 7 days OR Amoxicillin-Clavulanate 875/125 mg PO bid for 7 days OR Cephalexin 250 mg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Doxycycline 100 mg PO bid for 7 days OR Clindamycin 300–400 mg PO qid for 7 days OR Sulfamethoxazole-Trimethoprim 1–2 double-strength tablets PO bid for 7 days
- Culture-directed antimicrobial therapy
- Streptococcus alone
- Preferred regimen: Penicillin V 250–500 mg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Erythromycin 250 mg PO qid for 7 days OR Clindamycin 300–400 mg PO qid for 7 days
- Methicillin-resistant Staphylococcus aureus
- Preferred regimen: Doxycycline 100 mg PO bid for 7 days OR Clindamycin 300–450 mg PO qid for 7 days OR Sulfamethoxazole-Trimethoprim 1–2 double-strength tablets PO bid for 7 days
- Impetigo, pediatric
- Empiric antimicrobial therapy (covering methicillin-susceptible Staphylococcus aureus and β-hemolytic streptococci)
- Limited number of lesions
- Preferred regimen: Mupirocin topically bid for 5 days OR Retapamulin topically bid for 5 days
- Numerous lesions or outbreaks of poststreptococcal glomerulonephritis
- Preferred regimen: Amoxicillin-Clavulanate 25 mg/kg/day of amoxicillin component PO bid for 7 days OR Cephalexin 25–50 mg/kg/day PO tid–qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Clindamycin 25–30 mg/kg/day PO tid for 7 days OR Sulfamethoxazole-Trimethoprim 8–12 mg/kg/day PO bid for 7 days
- Culture-directed antimicrobial therapy
- Streptococcus alone
- Preferred regimen: Penicillin V 60,000–100,000 U/kg PO qid for 7 days
- Alternative regimen (for penicillin-allergic patients): Erythromycin 40 mg/kg/day PO tid–qid for 7 days OR Clindamycin 20 mg/kg/day PO tid for 7 days
- Methicillin-resistant Staphylococcus aureus
- Preferred regimen: Clindamycin 25–30 mg/kg/day PO tid for 7 days OR Sulfamethoxazole-Trimethoprim 8–12 mg/kg/day PO bid for 7 days
References
- ↑ Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ; et al. (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clin Infect Dis. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910.
- ↑ Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL; et al. (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America". Clin Infect Dis. 59 (2): 147–59. doi:10.1093/cid/ciu296. PMID 24947530.